CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
February 1st 2023
The TRANSCNED CLL 004 trial met its primary endpoint of complete responses with the CAR-T cell therapy Breyanzi in patients with relapsed or refractory CLL or SLL.
January 30th 2023
Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.
January 19th 2023
The Food and Drug Administration approved Brukinsa for patients with chronic lymphocytic leukemia or small lymphocytic leukemia.
January 11th 2023
Life looks a bit different after my cancer diagnosis and the COVID-19 pandemic, making me even more grateful for the people in my life.
December 26th 2022
When cancer entered our life, fear was a constant. However, we tried to live as joyously as possible between check-ups.
December 14th 2022
Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica.
December 13th 2022
Patients with chronic lymphocytic leukemia tended to switch to another regimen or intensify their Calquence treatment quicker than those given Imbruvica, study results showed.
December 9th 2022
Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system.
November 16th 2022
After being diagnosed with cancer 13 years ago, I began to wonder if my diet had anything to do with it — so I made some changes to eat better.
November 1st 2022
I made a point to continue baking a weekly challah bread after I was diagnosed with blood cancer, and it proved to be therapeutic.
October 22nd 2022
After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.
October 14th 2022
Investigators of an expanded clinical trial have administered an investigational CAR-T cell therapy to the first patient with blood cancer.
July 5th 2022
Long-term clinical trial data showed that the use of Copiktra was associated with an increased rate of death and severe side effects for patients with chronic lymphocytic leukemia and small cell leukemia.
June 13th 2022
Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.
June 5th 2022
Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.
April 25th 2022
A panel of experts on the FDA’s Oncologic Drugs Advisory Committee voted that all future approvals of PI3K inhibitors to treat blood cancer be backed by randomized clinical trial data.
April 21st 2022
The pharmaceutical company developing a combination regimen of ublituximab plus Ukoniq (known as U2) pulled the drug duo’s indications for the treatment of multiple types of blood cancer after clinical trial results fell short of improving overall survival.
April 12th 2022
The FDA’s partial hold means that no new patients with either leukemia or lymphoma can be enrolled onto the trial.
April 12th 2022
Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia.
March 31st 2022
Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.
February 27th 2022
Regardless of a patient’s age, comorbidity status or disease risk, an expert from Memorial Sloan Kettering Cancer Center notes how targeted therapies have become the standard of care in treating chronic lymphocytic leukemia.
February 14th 2022
More research is necessary, says an expert, to improve responses to CAR-T cell treatments in patients with chronic lymphocytic leukemia.
January 7th 2022
Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.
December 20th 2021
The combination of Calquence and Rituxan may also be useful during the COVID-19 pandemic as it decreases infusion times and patient interactions, according to an expert.
December 18th 2021
There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.
December 14th 2021
Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.
December 14th 2021
The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.
December 13th 2021
Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.
December 12th 2021
Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.